Focused On-demand Library for Pleckstrin homology domain-containing family M member 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9Y4G2

UPID:

PKHM1_HUMAN

Alternative names:

162 kDa adapter protein

Alternative UPACC:

Q9Y4G2; Q6P2R5; Q8TEL9; Q9NPP5; Q9NYA0

Background:

Pleckstrin homology domain-containing family M member 1, also known as the 162 kDa adapter protein, plays a pivotal role in cellular processes by acting as a multivalent adapter protein. It regulates Rab7-dependent and HOPS complex-dependent fusion events in the endolysosomal system, coupling autophagic and endocytic trafficking pathways. This protein is essential for the late stages of endolysosomal maturation, facilitating the degradation of growth factor receptors and autophagosome clearance. Additionally, it supports the integrity of the Salmonella-containing vacuole (SCV) during microbial infections.

Therapeutic significance:

Given its involvement in osteopetrosis, both autosomal recessive and dominant forms, understanding the role of Pleckstrin homology domain-containing family M member 1 could open doors to potential therapeutic strategies. Its function in bone resorption and regulation of endolysosomal maturation highlights its potential as a target for treating bone density disorders.